Integrating <i>In Vitro</i> Performance and <i>In Vivo</i> Patient-Reported Outcomes of a Mometasone Furoate Nasal Spray Device: A Translational Evaluation
The liquid VP3 nasal spray device delivering mometasone furoate demonstrated reliable <i>in vitro</i> performance and favorable patient acceptability in UACS. The correspondence between deposition behavior and patient-reported tolerability supports its suitability for INCS delivery and warrants further evaluation in larger, longer-term studies.
Authors
- Francesca Buttini (ORCID: https://orcid.org/0000-0002-4472-4823)
- Giorgio Vitale
- F Lavorini
- Fabio Sonvico (ORCID: https://orcid.org/0000-0001-7372-1456)
- Alessandra Sorano
- Virginia Patterlini (ORCID: https://orcid.org/0009-0003-0522-8303)
- Giulia Fabietti
- Ludovica Benuzzi
Institutions
- University of Parma (IT)
- University of Florence (IT)
Publication Details
- Journal
- Journal of Aerosol Medicine and Pulmonary Drug Delivery
- Published
- 2026-02-04
- DOI
- https://doi.org/10.1177/19412711261420781
- Primary Topic
- Respiratory and Cough-Related Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00